Bioenvision no longer traded as merger with Genzyme concludes

By Lisa Kerner

Charlotte, N.C., Oct. 23 - The merger of Bioenvision, Inc. and Genzyme Corp. is complete, as Bioenvision stock officially ceased trading, according to a form 15 filing with the Securities and Exchange Commission.

Bioenvision shareholders approved the $345 million deal, which gives them $5.60 per share, on Monday.

Bioenvision is a New York biopharmaceutical company, and Genzyme is a Cambridge, Mass.-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.